Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study

OBJECTIVE: A phase 1 dose-escalation study of polatuzumab vedotin (pola) was conducted to assess safety, pharmacokinetics and preliminary antitumor activity of pola in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma. METHODS: Patients received pola (1.0 or 1.8 mg/kg) intraveno...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinoshita, Tomohiro, Hatake, Kiyohiko, Yamamoto, Kazuhito, Higuchi, Yusuke, Murakami, Satsuki, Terui, Yasuhito, Yokoyama, Masahiro, Maruyama, Dai, Makita, Shinichi, Hida, Yukari, Saito, Tomohisa, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767980/
https://www.ncbi.nlm.nih.gov/pubmed/33029633
http://dx.doi.org/10.1093/jjco/hyaa169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767980/
https://www.ncbi.nlm.nih.gov/pubmed/33029633
http://dx.doi.org/10.1093/jjco/hyaa169

Ejemplares similares